Prospective observational cohort study of bevacizumab combined with paclitaxel as the first-or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)

被引：0
|
作者：
Kondo, N. [1 ,11 ]
Yamamoto, Y. [2 ]
Yamashiro, H. [3 ]
Kashiwaba, M. [4 ]
Nakamura, R. [5 ]
Takahashi, M. [6 ]
Toh, U. [7 ]
Tsugawa, K. [8 ]
Narui, K. [9 ]
Tamaki, K. [10 ]
Yoshinami, T.
Ohtani, S. [12 ]
Kai, Y. [13 ]
Takano, T. [14 ]
Yanagita, Y. [15 ]
Morita, S. [16 ]
Toi, M. [17 ]
Ohno, S. [18 ]
机构：
[1] Nagoya City Univ Hosp, Dept Breast Surg, Nagoya, Aichi, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto, Japan
[3] Tenri Hosp, Dept Breast Surg, Nara, Japan
[4] Iwate Med Univ, Dept Surg, Morioka, Iwate, Japan
[5] Chiba Canc Ctr, Dept Breast Surg, 666-2 Nitonacho, Chiba 2608717, Japan
[6] NHO Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan
[7] Kurume Univ Hosp, Dept Surg, Kurume, Fukuoka, Japan
[8] St Marianna Univ, Sch Med Hosp, Div Breast & Endocrine Surg, Dept Surg, Kawasaki, Kanagawa, Japan
[9] Yokohama City Univ, Med Ctr, Dept Breast & Thyroid Surg, Yokohama, Kanagawa 232, Japan
[10] Nahanishi Clin Okinawa, Dept Breast Surg, Naha, Japan
[11] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Clin Oncol, Osaka, Japan
[12] Hiroshima City Hiroshima Citizens Hosp, Dept Breast Surg, Hiroshima, Japan
[13] Ueo Breast Canc Hosp, Dept Surg, Oita, Japan
[14] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan
[15] Gunma Prefectural Canc Ctr, Dept Breast Oncol, Ota, Japan
[16] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[17] Kyoto Univ, Grad Sch Med, Breast Surg, Kyoto, Japan
[18] Canc Inst Hosp JFCR, Ctr Breast Oncol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [41] Study on the efficacy and safety of sintilimab combined with nab-paclitaxel as second-line treatment for advanced or metastatic gastric cancer (GC)/ gastroesophageal junction (GEJ) cancer.
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Cheng, Xiaojiao
    Li, Qingli
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Tu, Shuiping
    Chen, Xiaobing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16016 - E16016
  • [42] Weekly Paclitaxel, Capecitabine, and Bevacizumab With Maintenance Capecitabine and Bevacizumab as First-Line Therapy for Triple-Negative, Metastatic, or Locally Advanced Breast Cancer: Results From the GINECO A-TaXel Phase 2 Study
    Ferrero, Jean-Marc
    Hardy-Bessard, Anne-Claire
    Capitain, Olivier
    Lortholary, Alain
    Salles, Bruno
    Follana, Philippe
    Herve, Robert
    Deblock, Mathilde
    Dauba, Jerome
    Atlassi, Mustapha
    Largillier, Remy
    CANCER, 2016, 122 (20) : 3119 - 3126
  • [43] Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS)
    Decoster, Lore
    Kenis, Cindy
    Naessens, Benedicte
    Houbier, Ghislain
    De Man, Marc
    Lambrecht, Guy
    Monsaert, Els
    Moons, Veerle
    Vergauwe, Philippe
    Preneni, Hans
    Van Cutsem, Eric
    Wildiers, Hans
    JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (02) : 93 - 101
  • [44] Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)
    Shinichi Komiyama
    Kazuyoshi Kato
    Yuki Inokuchi
    Hirokuni Takano
    Takashi Matsumoto
    Atsushi Hongo
    Mikiko Asai-Sato
    Atsushi Arakawa
    Shoji Kamiura
    Tsutomu Tabata
    Nobuhiro Takeshima
    Toru Sugiyama
    International Journal of Clinical Oncology, 2019, 24 : 103 - 114
  • [45] Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
    Kenjiro Aogi
    Kenichi Watanabe
    Masahiro Kitada
    Takafumi Sangai
    Shoichiro Ohtani
    Tomoyuki Aruga
    Hidetoshi Kawaguchi
    Tomomi Fujisawa
    Shigeto Maeda
    Takashi Morimoto
    Nobuaki Sato
    Shintaro Takao
    Satoshi Morita
    Norikazu Masuda
    Masakazu Toi
    Shinji Ohno
    International Journal of Clinical Oncology, 2022, 27 : 1793 - 1793
  • [46] Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
    Kenjiro Aogi
    Kenichi Watanabe
    Masahiro Kitada
    Takafumi Sangai
    Shoichiro Ohtani
    Tomoyuki Aruga
    Hidetoshi Kawagichi
    Tomomi Fujisawa
    Shigeto Maeda
    Takashi Morimoto
    Nobuaki Sato
    Shintaro Takao
    Satoshi Morita
    Norikazu Masuda
    Masakazu Toi
    Shinji Ohno
    International Journal of Clinical Oncology, 2021, 26 : 1237 - 1237
  • [47] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
  • [48] Mature results on metastatic breast cancer patients with prolonged (≥1 year) exposure to first-line bevacizumab combined with paclitaxel from a large observation study
    Schmidt, M.
    Schneeweiss, A.
    Foerster, F.
    Geberth, M.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Aktas, B.
    Kuemmel, S.
    CANCER RESEARCH, 2013, 73
  • [49] Efficacy, safety, and treatment decision-making in the AVANTI German observational study of first-line bevacizumab (BEV)-containing therapy for locally advanced, recurrent, or metastatic breast cancer (aBC)
    Mueller, V.
    Jakob, A.
    Aktas, B.
    Grafe, A.
    Fett, W.
    Maerz, W.
    Bruch, H.
    Pott, D.
    Klare, P.
    Boller, E.
    Kiewitz, C.
    Schneeweiss, A.
    CANCER RESEARCH, 2016, 76
  • [50] Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study
    Kikawa, Yuichiro
    Kotake, Takeshi
    Tsuyuki, Shigeru
    Kang, Yookija
    Takahara, Sachiko
    Fujimoto, Yuri
    Yamashiro, Hiroyasu
    Yoshibayashi, Hiroshi
    Takada, Masahiro
    Yasuoka, Rie
    Nakatsukasa, Katsuhiko
    Yamagami, Kazuhiko
    Suwa, Hirofumi
    Okuno, Toshitaka
    Nakayama, Ichiro
    Kato, Tatsushi
    Ogura, Nobuko
    Moriguchi, Yoshio
    Ishiguro, Hiroshi
    Kagimura, Tatsuo
    Taguchi, Tetsuya
    Sugie, Tomoharu
    Toi, Masakazu
    BREAST CANCER, 2022, 29 (05) : 796 - 807
12345